COMP <GO>
SDGR vs HRMY // RETURN ON INVESTED CAPITAL (ROIC)
Schrodinger Inc. (NASDAQ) VS. Harmony Biosciences Holdings Inc. (NASDAQ) • 15-METRIC TALLY: SDGR 2
— HRMY 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: HRMY
LAST: $29.99 (-2.85%) • MKT CAP: $2.24B
roic
-35.00%
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
roic
63.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SDGR VS. HRMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SDGR | HRMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 77.20% | -21.50 | HRMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 63.00% | -98.00 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.56% | 15.48% | -14.92 | HRMY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.00% | -84.00 | HRMY | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 18.30% | -58.70 | HRMY | /net-margins <GO> |
| Revenue Growth (YoY) | 23.30% | 21.50% | +1.80 | SDGR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.64 | 5.38 | -2.74 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 50.0 | +9.30 | SDGR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 11.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.24B | $2.25B | -$3.9M | HRMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SDGR REV | HRMY REV | SDGR GROSS % | HRMY GROSS % | SDGR FCF | HRMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $255.9M | $868.5M | 55.7% | 77.2% | $12.5M | $347.9M |
| FY 2024 | $207.5M | $714.7M | 63.6% | 78.1% | -$164.7M | $218.7M |
| FY 2023 | $216.7M | $582.0M | — | — | -$136.7M | $219.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SDGR // BETA —
HRMY // BETA —